Loop Capital Has Lowered Expectations for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM) had its target price decreased by stock analysts at Loop Capital from $57.00 to $52.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Loop Capital’s price target indicates a potential upside of 58.68% from the stock’s current price.

TEM has been the subject of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a research report on Tuesday. Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America raised their target price on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Finally, Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Stock Performance

TEM stock traded up $0.43 on Tuesday, hitting $32.77. 2,172,719 shares of the company’s stock traded hands, compared to its average volume of 3,829,887. Tempus AI has a 1-year low of $22.89 and a 1-year high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock has a fifty day moving average of $47.94 and a 200-day moving average of $47.28.

Insider Transactions at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. The trade was a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the transaction, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 865,041 shares of company stock valued at $35,917,673 over the last three months.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently bought and sold shares of the stock. First Horizon Advisors Inc. acquired a new position in shares of Tempus AI during the 3rd quarter worth approximately $30,000. Geode Capital Management LLC raised its holdings in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after acquiring an additional 539 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at $67,000. Vestor Capital LLC acquired a new stake in shares of Tempus AI during the 3rd quarter worth $153,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after purchasing an additional 2,765 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.